


Fig. 1A

- 1 JUIN 2004

```
                210                                                                 279
SEQ 15   (210)  VMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQG
SEQ 08   (206)  VVLEAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRHVEVSWGYPDTWSTPHSYFSLTFCIQVQG
SEQ 09   (211)  VVLEAVHKLKYENYTSSFFIRDIIKPDPPKNLQLRPLKNSRQVEVNWEYPDTWSTPHSYFSLTFCVQVQG
SEQ 10   (211)  VVVDAIHKLKYENYTSSFFIRDIIKPDPPKNLQLRPLKNSRQVEVNWEYPDTWSTPHSYFSLTFCVQVQG
SEQ 11   (211)  VVVDAIHKLKYENYTSRFFIRDIIKPDPPKNLQLRPLKNSRHVEISWEYPDTWSTPHSYFSLTFCVQVQG
SEQ 12   (206)  VVLEAVHKLKYENYTSSFFIRDIIKPDPPKNLQLRPLKNSRQVEVNWEYPDTWSTPHSYFSLTFCVQVQG
SEQ 13   (206)  VVLEAVHKLKYENYTSSFFIRDIIKPDPPKNLQLRPLKNSRHVEVSWEYPDTWSAPHSYFSLTFGVQVQG
SEQ 14   (211)  VVVDAIHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRHVEISWEYPDTWSIPHSYFSLMFGVQVQG

                280                                                         328
SEQ 15   (280)  KSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCS--
SEQ 08   (276)  KSKREKKDRIFTDKTSATVICRKNAKIRVQARDRYYSSFWSEWASVSCS--
SEQ 09   (281)  KNKREKK--LFMDQTSAKVTCHKDAKIRVQARDRYYSSSWSEWASVPCS--
SEQ 10   (281)  KNKREKK--LFMDQTSAKVTCHKDAKIRVQARDRYYSSSWSEWASVPCS--
SEQ 11   (281)  KNKREKK--LFMDQTSAKVTCHKDAKIRVQARDRYHSSSWSEWASVPCS--
SEQ 12   (276)  RNKREKK--LFMDQTSAKVTCHKDAKIRVQARDRYYSSSWSDWASVSCG--
SEQ 13   (276)  RNKREDR--LFMDQTSAKVVCHKDAKIRVQARDRYYSSSWSEWASVSLQSV
SEQ 14   (281)  KNKREKKDRLSVDKTSAKVVCHKDAKIRVQARDRYYSSSWSEWASVPCS--
```

Fig. 1B

- 1 JUN 2004



R16-51/wt-p35
wt-p40/wt-p35
CPM
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
8
16
32
64
128
256
512
1024
2048
4096
8192
blank
Fold-Dilution

Fig. 2



wt-p40/wt-p35
A16-94/wt-p35
B8-96/wt-p35
C2-22/wt-p35
CPM
12000
10000
8000
6000
4000
2000
0
40
80
160
320
640
1280
2560
5120
10240
20480
40960
81920
Fold-Dilution

Fig. 3

5/16



A3-48/wt-p35
wt-p40/wt-p35
CPM
8000
7000
6000
5000
4000
3000
2000
1000
0
40
80
160
320
640
1280
2560
5120
10240
20480
40960
81920
Fold-Dilution

Fig. 4



B2-52/wt-p35
wt-p40/wt-p35
CPM
10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
32
64
128
256
512
1024
2048
4096
Fold-Dilution

Fig. 5



B1-81/wt-p35
wt-p40/wt-p35
7000
6000
5000
4000
3000
2000
1000
0
CPM
8
16
32
64
128
256
512
1024
Fold-Dilution

Fig. 6



wt-p40/wt-p35
MW
A3-48/wt-p35
A16-94/wt-p35
B1-81/wt-p35
B2-52/wt-p35
B8-96/wt-p35
C2-22/wt-p35
p70
p35

Fig. 7



wt-p40 / wt-p35
C2-22/wt-p35
250
148
60
42
30
Estimated MW, kDal
20ul 15ul 10ul 5ul 20ul 15ul 10ul 5ul 2ul
Volume of protein solution

Fig. 8



C2-22/wt-p35
wt-p40/wt-p35
CPM
16000
14000
12000
10000
8000
6000
4000
2000
0
Concentration (picograms/ml)
925.000
462.500
231.250
115.625
57.813
28.906
14.453
7.227
3.613
1.807
0.903
0.452
0.226
0.113
0.056
0.028
0.014
0.007
0.004
0.002

Fig. 9



wt-p40/wt-p35
C2-22/wt-p35
Commercial cytokine standard
Interferon-gamma (pg/ml)
10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
5 ng/ml
1 ng/ml
0.2 ng/ml
No heterodimer
Heterodimer concentration (ng/ml)

Fig. 10



Fig. 11A

- 1 JUN 2004

- 1 JUN 2004

```
                138                                                                  207
SEQ_36   (138)  FKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAV
SEQ 26   (140)  FKAMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKPSLEELDFYKTKIKLCILLHAFRIRAV
SEQ 27   (140)  FKAMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKPSLEELDFYKTKIKLCILLHAFRIRAV
SEQ 28   (138)  FKTMNAKLLMNPKRQIFLDQNMLTAIDELLQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAV
SEQ 29   (138)  FKAMNAKLLMDPKRQIFLDQNMLAAIAELMQALNVNSETAPQKSSLEEPDFYKTKIKLCILLHAFRIRAV
SEQ 30   (138)  FKAMNAKLLMDPKRQIFLDQNMLAAIAELMQALNVNSETAPQKSSLEEPDFYKTKIKLCILLHAFRIRAV
SEQ 31   (138)  FKTMNAKLLMNPKRQIFLDQNMLTAIDELLQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAV
SEQ 32   (138)  FKTMNAKLLMNPKRQIFLDQNMLTAIDELLQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAV
SEQ 33   (138)  FKAMNAKLLMDPKRQIFLDQNMLAAIAELMQALNVNSETAPQKSSLEEPDFYKTKIKLCILLHAFRIRAV
SEQ 34   (138)  FKAMNAKLLMDPKRQIFLDQNMLAAIAELMQALNVNSETAPQKSSLEEPDFYKTKIKLCILLHAFRIRAV
SEQ 35   (138)  FKTMNAKLLMNPKRQIFLDQNMLTAIDELLQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAV

                208         219
SEQ_36   (208)  TIDRVTSYLNAS
SEQ 26   (210)  TIDRMMSYLNSS
SEQ 27   (210)  TINRMMSYLNSS
SEQ 28   (208)  TINRMMSYLNSS
SEQ 29   (208)  TINRMMSYLNSS
SEQ 30   (208)  TINRMMSYLNSS
SEQ 31   (208)  TINRMMSYLNSS
SEQ 32   (208)  TINRMMSYLNSS
SEQ 33   (208)  TINRMMSYLNSS
SEQ 34   (208)  TIDRMMSYLNSS
SEQ 35   (208)  TINRMMSYLNSS
```

Fig. 11B



wt-p40/wt-p35
C2-22/R2-571
3H-thymidine (CPM)
97500
65000
32500
0
6.25
3.13
1.56
0.78
0.39
0.20
0.10
0.05
0.02
0.01
0.01
0.00
heterodimer (ng/ml)

Fig. 12



C2-22/R2-571
wt-p40/wt-p35
0
2
10
50
Heterodimer [ng/ml]
45,900.00
38,250.00
30,600.00
22,950.00
15,300.00
7,650.00
IFN-gamma [pg/ml]

Fig. 13



Multimeric forms
p-70
p-35
dilution of
C2-22/R2-571
wt 1 1:2 1:4 1:8 1:16 1:32 MW wt

Fig. 14